Education
About Us
Working with TipRanks
Follow Us
Evotec AG (EVO)
NASDAQ:EVO
EVO Stock Chart & Stats
$2.90
-$0.25(-5.45%)
At close: 4:00 PM EST
$2.90
-$0.25(-5.45%)
Day’s Range― - ―
52-Week Range$2.84 - $5.10
Previous CloseN/A
Volume32.72K
Average Volume (3M)68.00K
Market Cap
$1.06B
Enterprise Value$1.58B
Total Cash (Recent Filing)$237.27M
Total Debt (Recent Filing)$484.62M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Apr 01, 2026EPS Estimate
0.03Last Dividend Ex-Date
Jan 11, 2019Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding355,554,170
10 Day Avg. Volume94,867
30 Day Avg. Volume68,002
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)1.49
Price to Sales (P/S)1.78
P/FCF Ratio-12.45
Enterprise Value/Market Cap1.50
Enterprise Value/Revenue2.09
Enterprise Value/Gross Profit19.31
Enterprise Value/Ebitda-17.86
Forecast
1Y Price Target
$6.00Price Target Upside106.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.27
Revenue Forecast (FY)$901.77M
Bulls Say, Bears Say
Bulls Say
AI And Technological AdvancementsEvotec's AI capabilities are validated by broad partnerships and encouraging clinical progresses, highlighting its comprehensive integration in drug discovery and development.
Cost EfficiencyEvotec is on track to achieve €60M in cost-saving in 2025 and plans for an additional 50M cost-cut in the future.
Strategic PartnershipsThe breadth of pharma partnerships and clinical progress of partnered molecules provides platform validation and could generate significant upside through milestone and royalty payments.
Bears Say
Growth UncertaintyThe sale of the EU JEB business raises questions about long-term growth of the segment broadly and adds some uncertainty to the company's near-term growth.
Market ConditionsSoftness in biotech funding could continue to bite into near-term revenues.
Revenue ChallengesDPD revenue disappoints again, with Evotec reporting total revenue of €164M during 3Q25, down 11% YoY and 4% QoQ, which was below estimates.
Evotec AG News
EVO FAQ
What was Evotec AG’s price range in the past 12 months?
Evotec AG lowest stock price was $2.84 and its highest was $5.10 in the past 12 months.
What is Evotec AG’s market cap?
Evotec AG’s market cap is $1.06B.
When is Evotec AG’s upcoming earnings report date?
Evotec AG’s upcoming earnings report date is Apr 01, 2026 which is in 130 days.
How were Evotec AG’s earnings last quarter?
Evotec AG released its earnings results on Nov 05, 2025. The company reported -$0.138 earnings per share for the quarter, missing the consensus estimate of -$0.077 by -$0.061.
Is Evotec AG overvalued?
According to Wall Street analysts Evotec AG’s price is currently Undervalued.
Does Evotec AG pay dividends?
Evotec AG pays a Monthly dividend of $0.072 which represents an annual dividend yield of N/A. See more information on Evotec AG dividends here
What is Evotec AG’s EPS estimate?
Evotec AG’s EPS estimate is 0.03.
How many shares outstanding does Evotec AG have?
Evotec AG has 355,554,170 shares outstanding.
What happened to Evotec AG’s price movement after its last earnings report?
Evotec AG reported an EPS of -$0.138 in its last earnings report, missing expectations of -$0.077. Following the earnings report the stock price went down -15.869%.
Which hedge fund is a major shareholder of Evotec AG?
Currently, no hedge funds are holding shares in EVO
Evotec AG Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (106.90% Upside)
$6.00 (106.90% Upside)
Blogger Sentiment
Bullish
EVO Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.28%
12-Months-Change
Fundamentals
Return on Equity
-17.46%
Trailing 12-Months
Asset Growth
-6.25%
Trailing 12-Months
Company Description
Evotec AG
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
EVO Company Deck
EVO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a challenging environment for Evotec, with significant headwinds in the D&PD segment and overall revenue declines. However, the company showcases strong growth in the Biologics segment, transformational strategic partnerships, and effective cost reduction efforts. These positive developments, particularly the Sandoz deal and asset pipeline progression, suggest an optimistic outlook despite current challenges.View all EVO earnings summariesEVO Stock 12 Month Forecast
Average Price Target
$6.00
▲(106.90% Upside)
Technical Analysis
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Collegium Pharmaceutical
―
Ownership Overview
―
Insiders
0.08% Mutual Funds
1.82% Other Institutional Investors
97.70% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---